Bortezomib Injection, Powder, Lyophilized, For Solution
Product Images NDC 43598-426

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Bortezomib (NDC 43598-426). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Dr.reddy's Laboratories, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Cartonlabel (Cartonlabel)

This is a description of a medication called Bortezomib by Dr. Reddy's Laboratories. It contains 3.5 mg of bortezomib and 35 mg of mannitol in each vial for intravenous or subcutaneous use. It is a cytotoxic agent and must be diluted before use. The usual dosage and storage instructions are provided in the package insert. Reconstitution information is provided for intravenous use. The medication must be protected from light and any unused portion should be discarded. The package dimensions are 40 mm x 37 mm x 65 mm. The GTIN is 1034359842607 and the Code No is AP/DRUGS/41/2006.*

FDA Label Image

Figure1 (Figure1)

This appears to be a graph or chart displaying the percentage of patients over a certain period of time, with different categories labeled on the X-axis. However, without further context it is difficult to understand the full meaning or purpose of the information presented.*

FDA Label Image

Figure2 (Figure2)

FDA Label Image

Figure3 (Figure3)

FDA Label Image

Figure4 (Figure4)

This appears to be a report or analysis of treatment outcomes for patients using Bortezomib and Dexamethasone. The table provides data on the number of patients and the survival rates at a particular time point for each treatment. The "p-value from log-rank fest" may refer to statistical analysis of the data to test for significance. No further context or details are available.*

FDA Label Image

Figure5 (Figure5)

FDA Label Image

Figure6 (Figure6)

This is a chart showing the percentage of subjects alive and hazard ratio along with a graph representing the survival rate of subjects at risk over a course of 108 months from randomization. The subjects were given either VGR-CAP or R-CHOP.*

FDA Label Image

Stickerlabel (Stickerlabel)

This appears to be the label for a medication called Bortezomib For Injection that is administered intravenously with 0.9% sodium chloride. The label includes instructions on how to prepare the medication to achieve certain concentrations and to place stickers on the vial and syringe. There are also references to a package insert for full instructions. There is a scoreline on the label, but its purpose is not clear.*

FDA Label Image

Chemical Structure (Structure)

FDA Label Image

Viallabel (Viallabel)

The text is a description of a medication called Bortezomib, available in a single-dose vial containing 3.5 mg/vial of the active ingredient and 35 mg of mannitol. The medication is a cytotoxic agent intended for intravenous or subcutaneous use and must be diluted before use. The package insert contains dosage information, and instructions specify that any unused portion should be discarded. The medication is to be stored at 20°C to 25°C (68°F to 77°F), protected from light, and without preservatives. The drug is distributed by Dr. Reddy’s Laboratories Inc. in Princeton, NJ, and made in India.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.